John Edwards, MD, MBA

The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials

Introduction: Lumateperone (ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that modulates serotonin, dopamine, and glutama...

Andrew Satlin , MD;

Kimberly Vanover , PhD;

Sharon Mates , PhD;

John Kane , MD;

John Edwards , MD, MBA;

Suresh Durgam , MD;

Robert Davis , PhD;

11/22/2019

Effect of Lumateperone (ITI-007) on Quality of Life and Functional Disability in the Treatment of Bipolar Depression

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. In a Phase 3 clinical ...

John Edwards , MD, MBA;

Eric Messamore ;

01/19/2023

Cardiometabolic Safety of Lumateperone (ITI-007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study

Background: Antipsychotic treatment of schizophrenia is often associated with increased rates of metabolic syndrome (MetSy), as defined by criteria for waist circumference, triglycerides,...

Suresh Durgam , MD;

Christoph U. Correll , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

John Edwards , MD, MBA;

Richard Chen , PhD;

10/08/2020